162 related articles for article (PubMed ID: 12173317)
21. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
[TBL] [Abstract][Full Text] [Related]
22. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial.
Fizazi K; Bosserman L; Gao G; Skacel T; Markus R
J Urol; 2013 Jan; 189(1 Suppl):S51-7; discussion S57-8. PubMed ID: 23234632
[TBL] [Abstract][Full Text] [Related]
23. Bone formation and resorption markers as diagnostic tools for bone metastases evaluation.
Galliera E; Luzzati A; Perrucchini G; Gagliano F; Colloredo Mels L; Banfi G; Corsi Romanelli MM; Drago L
Int J Biol Markers; 2012 Dec; 27(4):e395-9. PubMed ID: 23015396
[TBL] [Abstract][Full Text] [Related]
24. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease.
Coleman RE; Houston S; James I; Rodger A; Rubens RD; Leonard RC; Ford J
Br J Cancer; 1992 May; 65(5):766-8. PubMed ID: 1586605
[TBL] [Abstract][Full Text] [Related]
25. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease.
Vinholes JJ; Purohit OP; Abbey ME; Eastell R; Coleman RE
Ann Oncol; 1997 Dec; 8(12):1243-50. PubMed ID: 9496390
[TBL] [Abstract][Full Text] [Related]
26. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
Coleman RE; Major P; Lipton A; Brown JE; Lee KA; Smith M; Saad F; Zheng M; Hei YJ; Seaman J; Cook R
J Clin Oncol; 2005 Aug; 23(22):4925-35. PubMed ID: 15983391
[TBL] [Abstract][Full Text] [Related]
27. Bone turnover and biochemical markers in malignancy.
Kanis JA; McCloskey EV
Cancer; 1997 Oct; 80(8 Suppl):1538-45. PubMed ID: 9362420
[TBL] [Abstract][Full Text] [Related]
28. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
29. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
[TBL] [Abstract][Full Text] [Related]
30. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
[TBL] [Abstract][Full Text] [Related]
31. Biochemical bone turnover markers are useful tools to assess changes in bone metabolism in marmosets.
Angeliewa A; Budde M; Schlachter M; Hoyle NR; Bauss F
J Bone Miner Metab; 2004; 22(3):192-7. PubMed ID: 15108060
[TBL] [Abstract][Full Text] [Related]
32. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
Berenson JR; Vescio RA; Rosen LS; VonTeichert JM; Woo M; Swift R; Savage A; Givant E; Hupkes M; Harvey H; Lipton A
Clin Cancer Res; 2001 Mar; 7(3):478-85. PubMed ID: 11297237
[TBL] [Abstract][Full Text] [Related]
33. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.
Coleman R; Brown J; Terpos E; Lipton A; Smith MR; Cook R; Major P
Cancer Treat Rev; 2008 Nov; 34(7):629-39. PubMed ID: 18579314
[TBL] [Abstract][Full Text] [Related]
34. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
35. Urine products of bone breakdown as markers of bone resorption and clinical usefulness of urinary hydroxyproline: an overview.
Simsek B; Karacaer O; Karaca I
Chin Med J (Engl); 2004 Feb; 117(2):291-5. PubMed ID: 14975218
[TBL] [Abstract][Full Text] [Related]
36. Bisphosphonates and breast carcinoma.
Lipton A
Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
[TBL] [Abstract][Full Text] [Related]
37. Biochemical markers for detecting bone metastases in patients with breast cancer.
Moro L; Gazzarrini C; Crivellari D; Galligioni E; Talamini R; de Bernard B
Clin Chem; 1993 Jan; 39(1):131-4. PubMed ID: 8419037
[TBL] [Abstract][Full Text] [Related]
38. Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Major PP; Lipton A; Berenson J; Hortobagyi G
Cancer; 2000 Jan; 88(1):6-14. PubMed ID: 10618600
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonates and bone metastases: current status and future directions.
Krempien R; Niethammer A; Harms W; Debus J
Expert Rev Anticancer Ther; 2005 Apr; 5(2):295-305. PubMed ID: 15877526
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
